Compare · ATLN vs BIO
ATLN vs BIO
Side-by-side comparison of Atlantic International Corp. (ATLN) and Bio-Rad Laboratories Inc. (BIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATLN and BIO operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BIO is the larger of the two at $8.15B, about 111.3x ATLN ($73.2M).
- Over the past year, ATLN is down 50.9% and BIO is up 23.4% - BIO leads by 74.4 points.
- ATLN has hit the wire 11 times in the past 4 weeks while BIO has been quiet.
- BIO has more recent analyst coverage (12 ratings vs 0 for ATLN).
- Company
- Atlantic International Corp.
- Bio-Rad Laboratories Inc.
- Price
- $0.90-5.48%
- $304.08+1.04%
- Market cap
- $73.2M
- $8.15B
- 1M return
- -38.55%
- +4.80%
- 1Y return
- -50.91%
- +23.44%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- 1980
- News (4w)
- 11
- 0
- Recent ratings
- 0
- 12
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Latest ATLN
- Circle8 Awarded Two $20 Million Dutch Public Sector Contract Extensions, Demonstrating Positive Commercial Momentum Across the Public Sector
- Chairman & CEO Franke Guus Paul Wilhelm sold $308,783 worth of shares (308,783 units at $1.00), decreasing direct ownership by 2% to 12,207,287 units (SEC Form 4)
- SEC Form 424B3 filed by Atlantic International Corp.
- Atlantic International's Circle8 Awarded $175 Million Contract Extension From the Dutch Ministry Of Infrastructure (Rijkswaterstaat)
- Atlantic International Relaunches As Circle8, Reflecting Its Evolution Into A Global Technology and Workforce Solutions Platform
- Atlantic International Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Atlantic International Corp Regains Compliance With Nasdaq Listing Requirements
- SEC Form 424B3 filed by Atlantic International Corp.
- Atlantic International’s Circle8 Secures Minimum $52 Million Government Contract Award
- Atlantic International Reports Record First Quarter 2026 Revenue of $249.9 Million
Latest BIO
- RBC Capital Mkts resumed coverage on Bio-Rad Labs with a new price target
- Bio-Rad to Participate in Upcoming Investor Conferences
- Bio-Rad Reports First-Quarter 2026 Financial Results
- Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
- Bio-Rad Labs downgraded by Citigroup with a new price target
- Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
- Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
- Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference
- Bio-Rad Reports Third-Quarter 2025 Financial Results
- Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025